Athira Pharma, Inc.
4.0750-0.13 (-2.98%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · ATHA · USD
Key Stats
Market Cap
16.07MP/E (TTM)
-Basic EPS (TTM)
-15.40Dividend Yield
0%Recent Filings
8-K
Regains Nasdaq compliance
Athira Pharma regained Nasdaq compliance on October 2, 2025, after its common stock closed at or above $1.00 for ten straight business days, resolving a prior deficiency notice from October 16, 2024. This lifts the compliance cloud, stabilizing the company's listing status amid ongoing biotech challenges. Nasdaq closed the matter outright.
8-K
Athira enacts 10-for-1 split
Athira Pharma filed amendments to implement a 10-for-1 reverse stock split, effective September 17, 2025, slashing authorized common shares from 900 million to 90 million. This move aims to boost the share price above Nasdaq's $1 minimum bid threshold while enhancing liquidity and investor appeal. No action needed for shareholders. Yet risks linger if it fails to sustain compliance.
10-Q
Q2 FY2025 results
Athira Pharma's Q2 FY2025 results show sharp cost cuts after pausing fosgonimeton development, slashing R&D expenses 83% y/y to $3.7M while focusing on ATH-1105 for ALS. Operating loss narrowed to $7.3M from $28.0M y/y, with net loss at $7.0M or $(0.18) per share versus $(0.70) last year—EPS aligns with 39.1M diluted shares. Cash burn eased to $21.7M YTD, leaving $29.8M in cash and investments, enough for at least 12 months per management. No debt burdens or M&A events; free cash flow not disclosed in the 10-Q. Yet clinical trial delays loom large.
8-K
Athira's ATH-1105 Phase 1 success
Athira Pharma reported Q2 2025 financials, highlighting positive Phase 1 data for ATH-1105 in ALS: favorable safety, tolerability, dose-proportional pharmacokinetics, and CNS penetration in healthy volunteers. Cash dwindled to $29.8 million from $51.3 million year-start, with net loss shrinking to $7.0 million from $26.9 million, as R&D expenses plunged 83% after pausing fosgonimeton post-failed Alzheimer's trial. The company explores strategic alternatives with Cantor Fitzgerald to boost shareholder value. Cash burn accelerates risks.
8-K
Athira approves reverse split
Athira Pharma's stockholders approved key measures at its May 29, 2025, annual meeting, electing Joseph Edelman, John M. Fluke, Jr., and Grant Pickering as Class II directors through 2028. They ratified Ernst & Young as auditors for 2025 and greenlit a flexible reverse stock split—ratios of 5:1 to 20:1—at the board's discretion to trim authorized shares. This bolsters compliance amid Nasdaq pressures. Yet, execution hinges on board timing.
ALZN
Alzamend Neuro, Inc.
2.45+0.09
ATAI
ATAI Life Sciences N.V.
5.86-0.10
ATHE
Alterity Therapeutics Limited
4.70-0.06
AVIR
Atea Pharmaceuticals, Inc.
3.29+0.08
CYTOF
Altamira Therapeutics Ltd.
0.08+0.00
KALA
KALA BIO, Inc.
0.80-0.03
KLTO
Klotho Neurosciences, Inc.
0.52-0.01
KTTA
Pasithea Therapeutics Corp.
0.72-0.01
LYRA
Lyra Therapeutics, Inc.
5.83-0.12
NRSN
NeuroSense Therapeutics Ltd.
1.06-0.06